Effect of multidisciplinary pre-dialysis education in advanced chronic kidney disease: Propensity score matched cohort analysis

Nephrology ◽  
2012 ◽  
Vol 17 (5) ◽  
pp. 472-479 ◽  
Author(s):  
EUN JIN CHO ◽  
HAYNE CHO PARK ◽  
HYUN BAE YOON ◽  
KYUNG DON JU ◽  
HWAJUNG KIM ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Propensity Score ◽  
Cohort Analysis ◽  
Matched Cohort ◽  
Advanced Chronic Kidney Disease

scholarly journals Hyperuricemia as a Predictor of Progression of Chronic Kidney Disease: A Matched Cohort Analysis

2017 ◽  
Vol 08 (03) ◽  
pp. 178-197 ◽  
Author(s):  
Michiaki Kamiyama ◽  
Hiroshi Kataoka ◽  
Takahito Moriyama ◽  
Toshio Mochizuki ◽  
Kosaku Nitta
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Cohort Analysis ◽  
Matched Cohort

scholarly journals COVID-19 in chronic kidney disease: a retrospective, propensity score-matched cohort study

2021 ◽  
Author(s):  
Ahmet Burak Dirim ◽  
Erol Demir ◽  
Serap Yadigar ◽  
Nurana Garayeva ◽  
Ergun Parmaksiz ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Cohort Study ◽  
Kidney Disease ◽  
Propensity Score ◽  
Matched Cohort ◽  
Matched Cohort Study

Phosphate binders in patients with chronic kidney disease: Between the new and the old.

2019 ◽  
pp. 2-3
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Estimated Glomerular Filtration Rate ◽  
Chronic Kidney Disease Stage ◽  
Disease Stage ◽  
Phosphate Binders ◽  
Advanced Chronic Kidney Disease ◽  
Phosphate Retention ◽  
Stage 4 ◽  
Dietary Phosphate

Impaired phosphate excretion by the kidney leads to Hyperphosphatemia. It is an independent predictor of cardiovascular disease and mortality in patients with advanced chronic kidney disease (stage 4 and 5) particularly in case of dialysis. Phosphate retention develops early in chronic kidney disease (CKD) due to the reduction in the filtered phosphate load. Overt hyperphosphatemia develops when the estimated glomerular filtration rate (eGFR) falls below 25 to 40 mL/min/1.73 m2. Hyperphosphatemia is typically managed with oral phosphate binders in conjunction with dietary phosphate restriction. These drugs aim to decrease serum phosphate by binding ingested phosphorus in the gastrointestinal tract and its transformation to non-absorbable complexes [1].

Sign in / Sign up

Export Citation Format

Share Document